Mature pancreatic islets are the gold standard for transplantation-based approaches for islet replacement in type 1 and type 3c diabetes mellitus (T1D and T3cD), but this feature is offset by the scarcity of human cadaveric pancreas donors.
Stanford inventors have identified a treatment regimen that allows expansion of cardiomyocytes (CMs) derived from human induced pluripotent stem cells in vitro.
Stanford researchers have developed a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).